自动与手持乳腺超声用于早期乳腺癌术前评估的多中心前瞻性比较
本研究为三中心前瞻性研究,纳入659例新诊断早期乳腺癌患者,比较ABUS联合数字乳腺X线(DM)与HHUS联合DM的术前病灶评估能力。结果显示ABUS/DM对同侧额外癌的敏感度非劣效于HHUS/DM(71.9%比75.0%),对侧癌敏感度更高(86.7%比60.0%)。两组特异度无显著差异,ABUS可作为HHUS的可行替代方案。
要点
- ABUS/DM与HHUS/DM对同侧额外癌敏感度无显著差异,可用于术前范围评估。
- ABUS/DM对侧乳腺癌检出敏感度高于HHUS/DM,对侧筛查价值更突出。
- 两者特异度相近,ABUS在人力或时间受限时可替代HHUS行术前分期。
核心结论
- ABUS/DM对早期乳腺癌同侧额外癌的敏感度非劣效于HHUS/DM,对侧额外癌敏感度更高。
- ABUS/DM与HHUS/DM在检测同侧及对侧额外癌方面特异度均相似。
- ABUS可作为早期乳腺癌术前分期的可行替代方案,适用于HHUS资源受限场景。
研究设计与样本
- 前瞻性多中心研究,在3家机构开展,纳入时间为2019年10月至2021年4月。
- 纳入659例新诊断早期乳腺癌且腋窝无可触及淋巴结、计划手术的患者,平均年龄50.5±9岁。
- 患者均接受ABUS、HHUS及数字乳腺X线检查,比较两种超声联合DM的诊断效能。
- 主要结局为ABUS/DM与HHUS/DM检出额外同侧或对侧癌的敏感度,预设非劣效界值为5%。
- 特异度作为次要结局进行评估。
关键影像表现/征象
- 所有指标癌(index cancer)均被ABUS/DM与HHUS/DM检出,检出率为100%。
- ABUS/DM检出同侧额外癌的敏感度为71.9%,HHUS/DM为75.0%。
- ABUS/DM检出对侧额外癌的敏感度为86.7%,HHUS/DM为60.0%。
诊断标准与关键数值
- 同侧额外癌敏感度:ABUS/DM为71.9%,HHUS/DM为75.0%,P=0.617,达到非劣效。
- 对侧额外癌敏感度:ABUS/DM为86.7%,HHUS/DM为60.0%,P=0.046,差异有统计学意义。
- 同侧额外癌特异度:ABUS/DM为97.7%,HHUS/DM为97.0%,P=0.317,无显著差异。
- 对侧额外癌特异度:ABUS/DM为97.8%,HHUS/DM为98.3%,P=0.467,无显著差异。
- 非劣效检验预设界值为5%,用于比较ABUS/DM与HHUS/DM对同侧额外癌敏感度。
临床应用与阅片要点
- ABUS标准化采图、可重复阅片,适合用于早期乳腺癌术前双侧乳腺范围评估。
- 对侧乳腺额外癌检出率较高,术前ABUS可帮助发现常规流程中易漏诊的对侧病灶。
- 在HHUS时间或人员配置受限时,可考虑ABUS/DM替代HHUS/DM进行术前超声分期。
- ABUS与HHUS特异度均较高且相近,但任何可疑额外病灶仍需结合其他影像或病理确认。
局限性
- 研究仅纳入早期乳腺癌且腋窝无可触及淋巴结的患者,结果可能不适用于局部晚期或腋窝阳性患者。
- 未报告是否进行随机化分组或超声操作者经验的一致性检验情况。
- 研究未提供组织病理作为所有额外癌灶的独立参考标准的具体确认流程细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare automated breast ultrasound (ABUS) and handheld breast ultrasound (HHUS) as adjuncts to digital mammography (DM) for preoperative assessment of local tumor extent in women with newly diagnosed early-stage breast cancer.
MATERIALS AND METHODS: In this prospective study conducted at three institutions, women with newly diagnosed early-stage breast cancer and no palpable axillary nodes scheduled for surgery underwent ABUS and HHUS adjunct to DM between Oct 2019 and Apr 2021. The primary outcome was the sensitivity of ABUS with DM (ABUS/DM) and HHUS with DM (HHUS/DM) for detecting additional ipsilateral or contralateral cancers beyond the index cancer. ABUS/DM was evaluated for noninferiority with a prespecified margin of 5%. Specificity was assessed as a secondary outcome.
RESULTS: A total of 659 patients (mean age, 50.5 ± 9 years) were included. Seventy-nine patients (12.0%) had additional cancers: 64 ipsilateral (51 multifocal, 13 multicentric) and 15 contralateral. For index cancers, both ABUS/DM and HHUS/DM achieved 100% detection. ABUS/DM showed noninferior sensitivity to HHUS/DM for additional ipsilateral cancers (71.9% vs. 75.0%; p = 0.617) and higher sensitivity than HHUS/DM for contralateral cancers (86.7% vs. 60.0%; p = 0.046). Specificity did not differ significantly between ABUS/DM and HHUS/DM for additional ipsilateral (97.7% vs. 97.0%; p = 0.317) or contralateral (97.8% vs. 98.3%; p = 0.467) cancers.
CONCLUSION: ABUS/DM showed noninferior sensitivity to HHUS/DM, with similar specificity for detecting additional ipsilateral and contralateral breast cancers in early-stage breast cancer. ABUS may serve as a feasible alternative to HHUS for preoperative staging in early-stage breast cancer.
KEY POINTS: Question Is automated breast ultrasound (ABUS) noninferior to handheld ultrasound (HHUS), each with digital mammography (DM), in preoperative staging of tumor extent in early-stage breast cancer? Findings ABUS/DM demonstrated noninferior sensitivity to HHUS/DM, with similar specificity for detecting additional ipsilateral and contralateral cancers in early-stage breast cancer. Clinical relevance ABUS may serve as a feasible alternative to HHUS for preoperative staging in early-stage breast cancer, particularly in clinical settings where the HHUS use is constrained by limited staffing resources and time restrictions.
引用
- Choi, Choi, Chung, et al. Comparison of automated breast ultrasound and hand-held breast ultrasound in preoperative evaluation of early-stage breast cancer: a multicenter prospective study. Eur Radiol. 2026. PMID: 42270856. doi:10.1007/s00330-026-12678-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。